BeiGene (02616) will showcase five of its latest research achievements at AACR 2025.

The latest preclinical research results of five self-developed Innovative Drugs by Basestone Pharmaceuticals (02616) will be showcased at the annual meeting of the American Association for Cancer Research (AACR).

Zhitong FinanceApr 23 22:05 ET

Hong Kong stocks have fluctuated | The Innovative Drugs Concept has seen significant gains. Institutions state that there is no need to pay tariffs on the licensing fees for Innovative Drugs, and support policies for Innovative Drugs are expected to be gr

The Innovative Drugs Concept has seen significant growth, as of the time of reporting, LAEKNA-B (02105) is up 13.16%, priced at 12.04 Hong Kong dollars; BRII-B (02137) is up 12.35%, priced at 1.82 Hong Kong dollars; CSTONE PHARMA-B (02616) is up 10.88%, priced at 2.65 Hong Kong dollars; BEIGENE (06160) is up 8.27%, priced at 148 Hong Kong dollars; HBM HOLDINGS-B (02142) is up 7.41%, priced at 7.68 Hong Kong dollars.

Zhitong FinanceApr 14 03:38 ET

More Unpleasant Surprises Could Be In Store For CStone Pharmaceuticals' (HKG:2616) Shares After Tumbling 31%

Simply Wall StApr 10 18:44 ET

CSTONE PHARMA-B (02616) completed the placement of 80 million shares, raising approximately 0.232 billion Hong Kong dollars.

CSTONE PHARMA-B (02616) announced that all conditions for the placement have been met, and the placement has been completed in April 2025...

Zhitong FinanceApr 10 07:26 ET

CSTONE PHARMA-B (02616.HK) received a Shareholding increase of 0.56 million shares by CEO and Executive Director Yang Jian, with a total Shareholding increase of 10.359 million shares.

Gelonghui, April 9 - CSTONE PHARMA-B (02616.HK) announced that the Chief Executive Officer, President of R&D, and Executive Director Yang Jianxin informed that from April 2 to April 7, 2025, he purchased a total of 0.56 million shares in the open market using his own funds, with a purchase price per share ranging from HKD 2.26 to HKD 3.29. Since assuming the position of CEO in August 2022, Yang Jianxin has cumulatively purchased a total of 10.359 million shares, at a purchase price per share ranging from HKD 0.82 to HKD 4.60. After this share purchase, Yang Jianxin holds a total equivalent to the company's announced date.

Gelonghui FinanceApr 9 00:32 ET

Express News | CStone Pharmaceuticals - Further Increase in Shareholding by CEO and Executive Director

ReutersApr 9 00:28 ET

Cornerstone Pharmaceuticals received a Shareholding increase of 0.36 million shares from Yang Jianxin, with a price of 2.39 Hong Kong dollars per share.

According to the latest information from the Hong Kong Stock Exchange, on April 7, Yang Jianxin increased his shareholding in Cornerstone Pharmaceutical (02616) by 0.36 million shares, at a price of 2.39 Hong Kong dollars per share, totaling 0.8604 million Hong Kong dollars. After the increase, the latest number of shares held is approximately 70.0843 million shares, with a latest holding ratio of 5.46%.

Sina Hong Kong StocksApr 8 20:00 ET

Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%. The impact of China Securities Co.,Ltd.'s tariff policy on the Industry Chain of pharmaceuticals still has uncertainties.

Jinwu Finance | Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%, HBM HOLDINGS-B (02142) down 25.43%, CUTIA-B (02487) down 25.13%, Yiming Angke-B (01541) down 24.73%, CSTONE PHARMA-B (02616) down 24.68%, LAEKNA-B (02105) down 24.38%, WUXI BIO (02269) down 24.02%, JACOBIO-B (01167) down 23.72%, and WUXI XDC (02268) down 23.45%. According to multiple sources.

Jinwu Financial NewsApr 7 01:23 ET

[Brokerage Focus] China Securities Co., Ltd. is Bullish on the Innovative Drugs Industry which is currently not affected by tariffs.

Jinwu Financial News | China Securities Co.,Ltd. stated that the impact of tariff policies on the Pharmaceutical Industry Chain is quite complex and may still have uncertainties. In the recent tariffs imposed by the USA on China, Pharmaceuticals are not currently involved. At this point, the firm is Bullish on the Innovative Drugs sector, the opportunities for domestic share increases in Medical Devices and Blood Products under autonomous control, and the Traditional Chinese Medicine, pharmacies, and distribution sectors focused on domestic demand, which are not significantly affected by tariffs. In the long run, going abroad should still be an important Global Strategy for pharmaceutical companies, and the firm firmly believes in the incremental opportunities brought by overseas expansion. The firm pointed out that 1) Innovative Drugs: Currently, going overseas mainly involves BD collaborations.

Financial NewsApr 6 20:42 ET

These Analysts Just Made An Incredible Downgrade To Their CStone Pharmaceuticals (HKG:2616) EPS Forecasts

Simply Wall StApr 2 19:55 ET

Hong Kong Stock Morning Report | Trump announces the implementation of so-called 'reciprocal tariff' measures. Deloitte states that the IPO financing amount in the Hong Kong market in the first quarter has increased nearly three times year-on-year.

① The Shanghai branch of the central bank issued the "2025 Shanghai Crediting Policy Guidelines." ② Trump announced the implementation of what is called "reciprocal tariffs," and several trading partners have indicated they will retaliate. ③ Tesla's delivery volume in the first quarter was 0.337 million vehicles, a decrease of 13% compared to the same period last year. ④ Deloitte: The IPO financing amount in Hong Kong's market in the first quarter increased by 287% year-on-year.

cls.cnApr 2 19:12 ET

Cornerstone Pharmaceuticals (02616) fell by 4.06% and plans to conduct a placement at a 14.99% discount, with last year's revenue down 12.2% year-on-year.

Jinwu Financial News | 基石药业 (02616) fell over 13% in early trading, and as of the time of writing, it has dropped by 4.06%, reporting at HKD 3.31, with a trading volume of HKD 73.37 million. In terms of news, 基石药业 announced that it plans to place a maximum of 80 million placement shares, which would account for approximately 5.86% of its issued share capital as expanded by the placement and issuance of all placement shares. The placement price per share is HKD 2.933, which represents a discount of about 14.99% compared to the closing price of the previous trading day. If all placement shares are fully placed, the estimated total amount and net amount (after deducting placement commissions and other related costs and professional fees) will be respectively...

Jinwu Financial NewsApr 2 03:18 ET

CSTONE PHARMA-B (02616.HK) plans to place a maximum of 80 million shares at a discount of approximately 14.99%, raising about 0.235 billion HKD.

On April 2, Gelonghui reported that CSTONE PHARMA-B (02616.HK) announced that on April 2, 2025 (before trading hours), the company and the placement agent (Morgan Stanley) entered into a placement agreement. According to this agreement, the company conditionally agrees to place a total of 80 million placement shares to no less than six subscribers through the placement agent at a price of HKD 2.933 per placement share. The placement price of HKD 2.933 per placement share is approximately 14% discount to the closing price of HKD 3.45 per share reported on the Stock Exchange on April 1, 2025 (the last full trading day immediately before the placement agreement date).

Gelonghui FinanceApr 1 20:08 ET

Express News | CStone Pharmaceuticals - to Place Aggregate of 80 Mln Placing Shares at HK$2.933 per Share

ReutersApr 1 20:01 ET

Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.

① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.

cls.cnApr 1 03:04 ET

Understanding the 2024 annual performance of Stone Pharmaceutical (02616) in one picture: licensing fees exceeded 0.2321 billion yuan, and the commercialization path is increasingly clear.

In 2024, CSTONE PHARMA-B (02616) showed a significant improvement in financial performance year-on-year: total revenue during the period was 0.4072 billion yuan, of which royalties and licensing fees amounted to 0.2321 billion yuan; the loss for the year decreased by 71.5%.

Zhitong FinanceMar 28 02:41 ET

Express News | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

ReutersMar 27 07:55 ET

Express News | CStone Pharmaceuticals - Loss for Year Was RMB91.2 Mln

ReutersMar 27 04:32 ET

CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 27 04:30 ET · Announcements

Hong Kong Stock Concept Tracking | The USA AACR Annual Meeting is about to be held, and domestic Innovative Drugs are accelerating the construction of Global competitiveness (attached concept stocks).

The AACR Annual Meeting will be held in Chicago, USA from April 25 to 30, 2025, local time.

Zhitong FinanceMar 26 22:50 ET